Europska Unija - hrvatski - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agenti za dermatitis, isključujući kortikosteroide - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig  - crisaborole - dermatitis, atopic - ostali dermatološki pripravci - staquis naznačeno za liječenje blage do umjerene atopijski dermatitis u odraslih i pedijatrijska bolesnika od 2-x godina s ≤ 40% površine tijela (bsa) utjecaj.

Europska Unija - hrvatski - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitis, atopic - ostali dermatološki pripravci - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatitis, atopic - ostali dermatološki pripravci - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atopic - ostali dermatološki pripravci - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.

Hrvatska - hrvatski - Ecolab

ecolab deutschland gmbh -

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - lisinoprilum, hydrochlorothiazidum - tableta - 20 mg + 25 mg - urbroj: jedna tableta sadrži 20 mg lizinoprila, u obliku lizinopril dihidrata i 25 mg hidroklorotiazida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - lisinoprilum, hydrochlorothiazidum - tableta - 10 mg + 12,5 mg - urbroj: jedna tableta sadrži 10 mg lizinoprila, u obliku lizinopril dihidrata i 12,5 mg hidroklorotiazida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

krka - farma d.o.o., radnička cesta 48, zagreb, hrvatska - lisinoprilum, hydrochlorothiazidum - tableta - 20 mg + 12,5 mg - urbroj: jedna tableta sadrži 20 mg lizinoprila, u obliku lizinopril dihidrata i 12,5 mg hidroklorotiazida

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pliva hrvatska d.o.o., prilaz baruna filipovića 25, zagreb, hrvatska - ciklosporin - kapsula, meka - 100 mg - urbroj: svaka kapsula sadrži 100 mg ciklosporina